Eton Pharmaceuticals (ETON) Director Jennifer McKie Adams Receives Award

What Happened
Jennifer McKie Adams, a director of Eton Pharmaceuticals, was granted 10,000 performance-vested restricted stock units (RSUs) on July 31, 2026. The award is reported as a derivative grant at a $0.00 acquisition price. These RSUs represent the right to receive up to 10,000 shares of Eton common stock if the performance condition is met.

Key Details

• Transaction date: July 31, 2026; Form 4 filed August 4, 2026.
• Transaction type/code: Award/Grant (A) of 10,000 RSUs; reported acquisition price $0.00 (derivative).
• Vesting/conditions: Vests in full and converts to shares only if the closing price of Eton common stock equals or exceeds $72.36 for one trading day at any time before July 31, 2029. If the market condition is not met by that date, the award is forfeited in its entirety.
• Shares owned after transaction: Not specified in the filing.
• Filing remark: The reporting person authorized another named person to file this Form 4 on her behalf for an indefinite duration.
• Timeliness: Form filed Aug 4, 2026 for a July 31, 2026 grant; Form 4s are typically required within two business days of the transaction (this filing was several days after the grant date).

Context
This is a conditional equity award (performance RSUs), not an open-market purchase or sale. The grant will only convert into shares if a specified market-price hurdle is met before the three-year deadline; if unmet, the award carries no value and will be forfeited. Such awards are common for aligning long-term executive/director incentives with shareholder value; they do not, by themselves, indicate the insider’s short-term view of the stock.